Skip to content

Effect of compound probiotics on gastrointestinal flora changes and clinical efficacy in patients with chronic gastritis infected with Hp

Effect of compound probiotics on gastrointestinal flora changes and clinical efficacy in patients with chronic gastritis infected with Hp

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026512
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic gastritis,peptic ulcer

Interventions

Gastritis control group:Tetralogy Placebo.
Probiotic group of chronic gastritis:Tetralogy Probiotics.
Peptic ulcer control group:Tetralogy Placebo.
Peptic ulcer probiotics group.:Tetralogy Probiotics.

Sponsors

Inner Mongolia people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years (excluding growth and aging factors); 2. Male and female living in North China; 3. The Han nationality; 4. The biopsy under gastroscope been diagnosed as chronic gastritis or peptic ulcer by pathology department of affiliated hospital of Inner Mongolia peoples Hospital, and was treated for the first time; 5. Patients need to test the 14C- breath test (UBT), or Rapid urease test (RUT), and one of them confirmed the existence of h. pylori infection in patients.

Exclusion criteria

Exclusion criteria: 1. Failing to take medicine as required; 2. Do not cooperate with the interviewer; 3. Pregnant and nursing women; 4. Taking drugs affecting gastrointestinal bacterial 1 month before collection of specimens; 5. During treatment and observation and take other drugs affecting intestinal flora; 6. Suffer from other serious diseases, and other diseases that affect the composition of gastrointestinal bacterial; 7. Repeatedly eradication of helicobacter pylori losers; 8. Patients who have been exposed to the taboo of gastroscopy.

Design outcomes

Primary

MeasureTime frame
bacterial diversity;Metagenomics;

Countries

China

Contacts

Public ContactGuo Ruifang

Inner Mongolia people's Hospital

grf_6872@163.com+86 18047192249

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026